BlueRock reports positive 36-month results from Parkinson’s cell therapy trial

BlueRock Therapeutics says that its Phase I trial of bemdaneprocel (BRT-DA01), a cell therapy for Parkinson’s disease, produced positive results at 36 months. The company claims the therapy remains safe, with evidence of implanted cell survival and clinical trends consistent with earlier observations. The trial enrolled 12 participants in an open-label, non-randomized study. All participants […] The post BlueRock reports positive 36-month results from Parkinson’s cell therapy trial appeared first on Longevity.Technology.